Copper 64 SAR trastuzumab/Copper 67 SAR trastuzumab (Clarity Pharmaceuticals)

N/A

Report date: 2025/11/24 17:31:46

Base Information

Drug NameCopper 64 SAR trastuzumab/Copper 67 SAR trastuzumab (Clarity Pharmaceuticals)

Drug Alias NameCu-64/67 SAR-trastuzumab64/67Cu-SAR-trastuzumab64Cu-SAR-trastuzumab/67Cu-SAR-trastuzumabcopper-64/67 sarcophagine-trastuzumab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Radioactive therapeutic agent +[7]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsIonising radiation emittersPositron-emission tomography enhancers

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesClarity Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesClarity Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A